Anokion to Participate in Autoimmune and Inflammatory Disease Panel at 2020 Biotech Showcase
CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Jan 8, 2020--
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that John A. Hohneker, M.D., president and chief executive officer of Anokion, will participate in an expert panel titled, “Autoimmune and Inflammatory Disease (AIID): Beyond the sledgehammer approach,” on January 13 at 8:00am PT at the 2020 Biotech Showcase in San Francisco. The panel will explore various therapeutic strategies being pursued by new companies in the space and how the autoimmune disease landscape is expected to evolve based on a more thorough understanding of the biology driving these diseases.
Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease. For more information, please visit http://www.anokion.com/.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200108005101/en/
CONTACT: Alicia Davis
THRUST Strategic Communications
KEYWORD: EUROPE SWITZERLAND UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Anokion SA
Copyright Business Wire 2020.
PUB: 01/08/2020 08:30 AM/DISC: 01/08/2020 08:30 AM